Professor Malcolm Stevens OBE to join Pharminox
Oxford, 19 January 2004 - Pharminox Ltd (“Pharminox” or “the Company”), the private UK oncology R&D company, today announced the appointment of Professor Malcolm Stevens OBE as Chief Scientific Officer and a member of the Board of Directors.
Professor Stevens has had a long and distinguished career in cancer research. Since 1980 he has been Director of the Cancer Research UK (formerly Cancer Research Campaign) Experimental Cancer Chemotherapy group now based at the University of Nottingham. While Professor of Experimental Cancer Chemotherapy at the University of Aston he was responsible for the discovery and early development of temozolomide, a treatment for glioma and astrocytoma brain tumours that is now approved throughout the world and is marketed by Schering-Plough under the trademark Temodaltm. Worldwide sales of Temodal in 2004 exceeded $450m. In addition to temozolomide, Professor Stevens has also been responsible for bringing five other experimental new cancer drugs into the clinic, including one other, bropirimine, which has received regulatory approval in Japan. In 1999 he was awarded an OBE for his services to cancer research in the UK.
Commenting on today’s announcement, Dr Chris Wright, Chairman of Pharminox, said, “The appointment of Malcolm Stevens is a real coup for Pharminox and we are delighted that he has agreed to join us. He has both an outstanding track record and an international reputation in cancer research, and we believe he will play a pivotal role in helping the Company achieve its objective of becoming a significant force in the discovery and development of new cancer treatments in the UK.”